Implantable, Hidden Continuous Glucose Monitoring Could Revolutionize Diabetes Care
By Johnny Rice Benzinga
DETROIT, MICHIGAN - March 19, 2025 (NEWMEDIAWIRE) - Paul Goode, President & CEO, GlucoTrack (NASDAQ: GCTK), was recently a guest on Benzingas All-Access.
GlucoTrack is a medical technology company whose two-year implantable Continuous Blood Glucose Monitoring (CBGM) technology provides discreet, accurate, real-time glucose readings. The companys vision is to create a future where diabetes management is automatic and inconspicuous, empowering people to live boldly and unapologetically.
Learn more here:
https://www.youtube.com/watch?v=xjn-_aLseTc&feature=youtu.be
Featured photo by Towfiqu barbhuiya on Unsplash .
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
This content was originally published on Benzinga . Read further disclosures here.
Copyright 2025 JCN Newswire . All rights reserved.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dallas County Schools Show Continued Progress in 2026 Accountability Ratings
- KB HOME OPENS BRIGHTON CROSSINGS, A NEW COMMUNITY PRICED FROM THE $460Ks WITHIN A DESIRABLE BRIGHTON, COLORADO MASTER PLAN
- Grabar Law Office Investigates Claims on Behalf of Symbotic Inc. (SYM) Investors Who Purchased Shares Prior to February 5, 2024
Create E-mail Alert Related Categories
Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share